Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems
Key Highlights
- ➤First-half revenue $10.89 million, up 6% year over year
- ➤First-half operating income $1.28 million, up 41% year over year
- ➤Medical sales $7.05 million, up 289% year over year
- ➤Fiscal 2027 guidance reiterated at flat to modest revenue growth
- ➤Three subsequent orders totaling approximately $7.19 million expected in fiscal 2028
- ➤Backlog $9.51 million, up 23% sequentially
Expert Statements
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“Fiscal 2027 is progressing well, with solid first-half revenue growth, meaningful gross margin expansion and strong improvement in operating profitability.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“Medical was again the primary growth driver, with first-half sales increasing 289%, led by strong demand for balloon coating and specialty stent-coating systems.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“We are particularly encouraged by the increasing adoption of our technology as customers move from development into commercial manufacturing.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“Looking ahead, we remain focused on expanding our installed base of production systems, supporting customers as they scale, and investing in the engineering, application development and commercial capabilities that will drive our next phase of growth.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“We continue to maintain our previously communicated expectation of flat to modest revenue growth for the full fiscal year.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“This outlook reflects the timing of several large, higher-value production platform orders, which can result in increased quarter-to-quarter variability as these systems become a larger portion of our business.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“With a strong and growing backlog and cash position, we believe we are well positioned to capitalize on the opportunities ahead and continue building long-term value for our shareholders.”
Steve Harshbarger, President and Chief Executive Officer of Sono-Tek
“We are extremely proud of our performance and long-term track record of revenue and importantly net income growth.”
Dr. Christopher L. Coccio, Executive Chairman of Sono-Tek
“Our first-half results reinforce the long-term strength of Sono-Tek’s ultrasonic coating technology platform and the strategic direction we have pursued for many years.”
Dr. Christopher L. Coccio, Executive Chairman of Sono-Tek
“The exceptional growth in our medical business demonstrates how our technology and application expertise are enabling customers to address increasingly demanding coating requirements in sophisticated medical-device applications.”
Dr. Christopher L. Coccio, Executive Chairman of Sono-Tek
“We believe this growth also reflects the broader opportunity to expand our role as customers move from development into commercial manufacturing and increasingly require greater precision, repeatability and process control.”
Dr. Christopher L. Coccio, Executive Chairman of Sono-Tek
“Over decades, Sono-Tek has built differentiated technology, deep application expertise and lasting customer relationships that continue to position us for future growth.”
Dr. Christopher L. Coccio, Executive Chairman of Sono-Tek
“We see opportunities to build on these strengths by expanding our presence in existing markets, developing new applications and supporting customers as their manufacturing requirements evolve.”
Dr. Christopher L. Coccio, Executive Chairman of Sono-Tek
“Together with our strong financial foundation and disciplined approach to investment, we believe these enduring strengths provide a solid platform for sustainable long-term growth and continued value creation for our shareholders.”
First Half Revenue Increased 6% to $10.9 Million; Gross Margin Expanded to 55%; Operating Income Increased 41%; Medical Market Sales Increased 289%
Reiterates Expectation of Flat to Modest Revenue Growth for FY 27 Reflecting Timing of Several Large Orders
Get started
Create a free account to read the full story.